Oncopeptides AB (ONCO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncopeptides AB (ONCO) has a cash flow conversion efficiency ratio of -23.926x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-156.43 Million ≈ $-16.83 Million USD) by net assets (Skr6.54 Million ≈ $703.59K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oncopeptides AB - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Oncopeptides AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Oncopeptides AB for a breakdown of total debt and financial obligations.
Oncopeptides AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncopeptides AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Biohit Oyj B
HE:BIOBV
|
0.040x |
|
Milux Corporation Bhd
KLSE:7935
|
0.023x |
|
Urbanise.com Ltd
AU:UBN
|
0.336x |
|
Orad-M
TA:ORAD
|
-0.035x |
|
MUI Properties Bhd
KLSE:3913
|
0.757x |
|
Veru Inc
NASDAQ:VERU
|
-0.166x |
|
Hipay Group SA
PA:ALHYP
|
0.066x |
|
OTRS AG
F:TR9
|
0.155x |
Annual Cash Flow Conversion Efficiency for Oncopeptides AB (2014–2024)
The table below shows the annual cash flow conversion efficiency of Oncopeptides AB from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Oncopeptides AB (ONCO) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr54.28 Million ≈ $5.84 Million |
Skr-260.57 Million ≈ $-28.04 Million |
-4.800x | +2.49% |
| 2023-12-31 | Skr56.78 Million ≈ $6.11 Million |
Skr-279.49 Million ≈ $-30.08 Million |
-4.922x | -244.49% |
| 2022-12-31 | Skr294.29 Million ≈ $31.67 Million |
Skr-420.51 Million ≈ $-45.25 Million |
-1.429x | +80.13% |
| 2021-12-31 | Skr210.87 Million ≈ $22.69 Million |
Skr-1.52 Billion ≈ $-163.19 Million |
-7.191x | -219.98% |
| 2020-12-31 | Skr576.90 Million ≈ $62.08 Million |
Skr-1.30 Billion ≈ $-139.53 Million |
-2.247x | -159.38% |
| 2019-12-31 | Skr797.01 Million ≈ $85.77 Million |
Skr-690.57 Million ≈ $-74.32 Million |
-0.866x | +18.00% |
| 2018-12-31 | Skr315.83 Million ≈ $33.99 Million |
Skr-333.73 Million ≈ $-35.91 Million |
-1.057x | -62.69% |
| 2017-12-31 | Skr418.00 Million ≈ $44.98 Million |
Skr-271.50 Million ≈ $-29.22 Million |
-0.650x | +83.59% |
| 2016-12-31 | Skr26.34 Million ≈ $2.83 Million |
Skr-104.26 Million ≈ $-11.22 Million |
-3.959x | -119.49% |
| 2015-12-31 | Skr-2.60 Million ≈ $-279.80K |
Skr-52.81 Million ≈ $-5.68 Million |
20.311x | +591.36% |
| 2014-12-31 | Skr7.61 Million ≈ $818.48K |
Skr-31.44 Million ≈ $-3.38 Million |
-4.134x | -- |
About Oncopeptides AB
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company's PDC platform desig… Read more